EGFR gene copy number alteration and mutation are highly variable and scientists have been challenged to define their prognostic significance in triple-negative breast cancer.

DEFB gene products are small antimicrobial proinflammatory peptides, and copy number variation (CNV) could reasonably influence susceptibility to infection and inflammation.

These deletions or duplications, also called copy-number changes, can change the dosage of a gene.